TriangleNCT03075527 · OUTCOME
Median Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 80% Confidence Interval
- Time frame
- OS is assessed from date of registration until date of death on-treatment or during follow-up. Survival data collection in long-term follow-up every 3-4 months. Median follow-up for survival is of 27.33 months with range (0.76 months - 50.40 months).
What was measured
OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.
Analysis population: The analysis population is comprised of eligible and treated patients.
Groups in this outcome
Tremelimumab + Durvalumab
Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
| Group | Source count |
|---|---|
| Tremelimumab + Durvalumab | 19 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Tremelimumab + Durvalumab | 9.76 | Not reported | 7.2 | 29.2 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.2
- upper Limit
- 29.2
- value
- 9.76
- denoms
- counts
- group Id
- OG000
- value
- 19
- units
- Participants
- description
- OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.
- dispersion Type
- 80% Confidence Interval
- groups
- description
- Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
- id
- OG000
- title
- Tremelimumab + Durvalumab
- param Type
- MEDIAN
- population Description
- The analysis population is comprised of eligible and treated patients.
- reporting Status
- POSTED
- time Frame
- OS is assessed from date of registration until date of death on-treatment or during follow-up. Survival data collection in long-term follow-up every 3-4 months. Median follow-up for survival is of 27.33 months with range (0.76 months - 50.40 months).
- title
- Median Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice